WO2001022969A3 - Vasopressin agonist formulation and process - Google Patents

Vasopressin agonist formulation and process Download PDF

Info

Publication number
WO2001022969A3
WO2001022969A3 PCT/US2000/026380 US0026380W WO0122969A3 WO 2001022969 A3 WO2001022969 A3 WO 2001022969A3 US 0026380 W US0026380 W US 0026380W WO 0122969 A3 WO0122969 A3 WO 0122969A3
Authority
WO
WIPO (PCT)
Prior art keywords
component
process
vasopressin agonist
agonist formulation
formulations
Prior art date
Application number
PCT/US2000/026380
Other languages
French (fr)
Other versions
WO2001022969A2 (en
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40616599A priority Critical
Priority to US09/406,165 priority
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of WO2001022969A2 publication Critical patent/WO2001022969A2/en
Publication of WO2001022969A3 publication Critical patent/WO2001022969A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having general structure (I), and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.
PCT/US2000/026380 1999-09-27 2000-09-26 Vasopressin agonist formulation and process WO2001022969A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40616599A true 1999-09-27 1999-09-27
US09/406,165 1999-09-27

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001526180A JP2003510280A (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and preparation
AU76152/00A AU7615200A (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process
CA 2385971 CA2385971A1 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process
MXPA02003191A MXPA02003191A (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process.
EP00965432A EP1216045A2 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process

Publications (2)

Publication Number Publication Date
WO2001022969A2 WO2001022969A2 (en) 2001-04-05
WO2001022969A3 true WO2001022969A3 (en) 2001-12-20

Family

ID=23606805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026380 WO2001022969A2 (en) 1999-09-27 2000-09-26 Vasopressin agonist formulation and process

Country Status (7)

Country Link
EP (1) EP1216045A2 (en)
JP (1) JP2003510280A (en)
CN (1) CN1391476A (en)
AU (1) AU7615200A (en)
CA (1) CA2385971A1 (en)
MX (1) MXPA02003191A (en)
WO (1) WO2001022969A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP2239012A3 (en) * 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
JP6423372B2 (en) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 Squibb Bristol Myers Co Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
WO1996022293A1 (en) * 1995-01-17 1996-07-25 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1999006409A1 (en) * 1997-07-30 1999-02-11 American Home Products Corporation Tricyclic vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
WO2000046227A1 (en) * 1999-02-04 2000-08-10 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
WO1996022293A1 (en) * 1995-01-17 1996-07-25 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1999006409A1 (en) * 1997-07-30 1999-02-11 American Home Products Corporation Tricyclic vasopressin agonists
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
WO2000046227A1 (en) * 1999-02-04 2000-08-10 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists

Also Published As

Publication number Publication date
MXPA02003191A (en) 2002-09-30
JP2003510280A (en) 2003-03-18
CN1391476A (en) 2003-01-15
EP1216045A2 (en) 2002-06-26
WO2001022969A2 (en) 2001-04-05
AU7615200A (en) 2001-04-30
CA2385971A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
CA2294031C (en) Self-emulsifying formulation for lipophilic compounds
CA2416685A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PL213199B1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2182200A1 (en) Formulations for Factor IX
MY129350A (en) Aripiprazole oral solution
IL140710A (en) Compositions for pulmonary delivery of active agents
IL138737A (en) Antitumoral pharmaceutical compositions comprising indolyl - 3 - glyoxylic acid derivatives
PT1094781E (en) Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
PT91246A (en) Process for the preparation of pharmaceutical compositions for endovenous administration, containing cyclosporin as active ingredient
CA2505520A1 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
CA2408685A1 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
CA2340052A1 (en) Pharmaceutical compositions containing lipase inhibitors and chitosan
CA2319680A1 (en) Compounds and compositions for delivering active agents
CA2362728A1 (en) Improved aqueous solubility pharmaceutical formulations
CA2277274A1 (en) Crystal form 0 of clarithromycin
CA2483199C (en) High drug load tablet of imatinib
CA2441260A1 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
AU6268894A (en) Compositions for oral delivery of active agents
AU5945396A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
EP1466594A3 (en) Stable pharmaceutical solution formulations for pressurised metered dose inhalers
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
AU7547196A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2442854A1 (en) Hsa-free formulations of interferon-beta
EP1468679A3 (en) Controlled release formulation containing tramadol

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965432

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 526180

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2385971

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003191

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008160090

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000965432

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000965432

Country of ref document: EP